TopicalDosed ingredient Cosmetic cross-reference

Octinoxate

CAS 5466-77-3

Octinoxate (CAS 5466-77-3) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 44 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Octinoxate

CAS Number

5466-77-3

UNII

4Y5P7MUD51

InChIKey

YBGZDTIWKVFICR-UHFFFAOYSA-N

ChEMBL ID

CHEMBL3183184

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredientnatural producttopical

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL3183184 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE NLM DailyMed 1 label row

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

Product	Ingredient	Active Moiety	Effective
THANKYOU FARMER Sun Project Moisture Sun	OCTINOXATE 4Y5P7MUD51	OCTINOXATE	20260505

SOURCE EMBL-EBI ChEMBL 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Potency	25418.13333333333 nM	3	-
-	AC50	3162.3 nM	1	-

SOURCE DrugCentral 44 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Macular degeneration	258	997.613	10025409
Chronic sinusitis	90	304	10009137
Paraesthesia oral	90	269.237	10057372
Procedural pain	90	260.484	10064882
Vaginal flatulence	39	158.398	10064227
Therapeutic product effect incomplete	111	140.787	10082200
Dyspepsia	97	134.571	10013946
Female genital tract fistula	40	132.593	10061149
Drug ineffective	312	126.484	10013709
Vaginal discharge	39	121.019	10046901
Proctitis	38	120.279	10036774
Squamous cell carcinoma of skin	44	116.565	10041834
Radiculopathy	39	112.508	10037779
Anal inflammation	21	87.961	10050247
Pyrexia	174	78.178	10037660
SARS-CoV-2 test negative	18	74.366	10084273
Frequent bowel movements	40	72.198	10017367
Oral candidiasis	39	71.369	10030963
Colitis ulcerative	42	70.859	10009900
Weight decreased	117	65.477	10047895
Skin atrophy	23	64.958	10040799
Infusion related reaction	96	62.684	10051792
Malaise	124	51.042	10025482
Proctalgia	22	50.164	10036772
Rectal haemorrhage	45	50.094	10038063
Colitis	44	48.88	10009887
Accident	21	48.417	10000369
Neoplasm skin	14	46.596	10029098
Ochronosis	7	44.636	10051253
Appendicolith	18	43.492	10074458
Haematochezia	44	43.246	10018836
Constipation	85	42.548	10010774
Nausea	172	35.083	10028813
Pain	147	34.726	10033371
Haemorrhoids	22	26.874	10019022
Appendicitis	18	26.462	10003011
Ventricular fibrillation	20	24.322	10047290
Erythema	54	22.098	10015150
Off label use	154	21.465	10053762
Language disorder	9	21.33	10074869
Cardiogenic shock	20	20.113	10007625
Body temperature increased	22	19.565	10005911
Transferrin saturation abnormal	4	19.518	10079855
Anal injury	4	19.146	10055023

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
OCTINOXATE	13369	SU	MTHSPL
Octinoxate	13369	SU	MTHSPL
octinoxate	13369	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Octinoxate used for in pharmaceutical contexts?

Octinoxate (CAS 5466-77-3) appears in DailyMed active-ingredient label rows, including THANKYOU FARMER Sun Project Moisture Sun.

What are the known adverse events for Octinoxate?

Octinoxate has 44 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Macular degeneration, Chronic sinusitis, Paraesthesia oral, Procedural pain, Vaginal flatulence. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Octinoxate also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Ethylhexyl Methoxycinnamate with EU status "restricted".

What clinical phase is Octinoxate in?

Octinoxate is rendered with ChEMBL max phase 4 (approved).